Sp1253
PANEL DISCUSSION / Q&A
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy. Mechanisms for dysfunction of esophageal smooth muscle function in EoE and GERD have been studied in bench models of human esophageal tissues. Understanding and targeting these mechanisms therapeutically may improve symptomatic outcomes in what are otherwise considered mucosal esophageal diseases.
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy. Mechanisms for dysfunction of esophageal smooth muscle function in EoE and GERD have been studied in bench models of human esophageal tissues. Understanding and targeting these mechanisms therapeutically may improve symptomatic outcomes in what are otherwise considered mucosal esophageal diseases.
Presenters
Baylor University Medical Center at Dallas
University of Southern California, Keck School of Medicine
Tracks
Related Products
DUPILUMAB IMPROVES HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS, REGARDLESS OF PRIOR HISTORY OF ESOPHAGEAL DILATION
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
IMPACT OF UP TO 6 MONTHS OF MEPOLIZUMAB TREATMENT FOR ADOLESCENTS AND ADULTS WITH EOSINOPHILIC ESOPHAGITIS IN THE SECOND PHASE OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
ACHALASIA IS STRONGLY ASSOCIATED WITH EOSINOPHILIC ESOPHAGITIS AND OTHER ALLERGIC DISORDERS
Concomitant esophageal dysmotility can be present in up to 2/3 of patients with EoE and GERD. Esophageal dysmotility contribute to symptoms in these patients and can be a reason for a suboptimal response to therapy…
LONGITUDINAL EFFECTS OF TREATMENT ON ESOPHAGEAL DYSMOTILITY IN EOSINOPHILIC ESOPHAGITIS
BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
